The CA Tumor Markers Testing Market size is estimated to reach $251.7 million by 2027, growing at a CAGR of 6.7% during the forecast period 2022-2027. The growth of the CA Tumor Markers Testing Market is greatly fueled by the increasing predominance of cancer and the growing adoption of diagnostic services and technologies. As per World Health Organization (WHO), cancer is a chief cause of loss of life globally. It was responsible for almost 10 million demises in 2020 or almost one in six demises. There is an upsurge in the rate of acceptance of diagnostic services and technologies that are more progressive than those formerly applied. Radioimmunoassay (RIA) is an in-vitro assay that assesses the existence of an antigen with very soaring sensitivity. Enzyme immunoassays (EIA) or enzyme-linked immunosorbent assays (ELISA) involve a blood or urine analysis that can assist in the diagnosis of numerous infections and inflammatory conditions. Real-time PCR techniques are an agreeable alternative for the investigation of cancer markers. 

CA Tumor Markers Testing Market Growth Drivers:

  • Surging Role of Radioimmunoassay (RIA):

The most typically utilized radioisotope for radioimmunoassay (RIA) is an isotope of iodine - termed iodine-125 (125I). Iodine-125 can be made with very high specific activity and with nearly 100% isotopic abundance. Carbohydrate antigen (CA) 19-9 is a kind of antigen discharged by pancreatic cancer cells. The CA 19-9 Radioimmunoassay (RIA) is a blood test that assesses the CA 19-9 level in the blood. Consequent to diagnosis, the CA 19-9 Radioimmunoassay (RIA) blood test can also be utilized for certain patients to watch the development of the ailment. The increasing role of radioimmunoassay (RIA) is therefore driving the growth of the CA Tumor Markers Testing Industry, thereby contributing to the CA Tumor Markers Testing Industry Outlook.

  • Soaring Applications of Enzyme Immunoassays (EIA) and PCR:

Enzyme-linked Immunoassays are quick with outcomes in 1 to 6 hours. During Enzyme Immunoassays (EIA), the process utilizes enzyme-labeled antibodies and antigens to discover the tiny biological molecules needed. The method utilizes the elementary immunology concept that an antigen fastens a particular antibody. Such antigen molecules, which can be recognized in a liquid sample, involve molecules like peptides, hormones and proteins. Quantitative real-time PCR can conclude gene duplications or deletions. Furthermore, melting curve investigation instantly after PCR can recognize tiny mutations, down to single base alterations. The soaring applications of Enzyme Immunoassays (EIA) and PCR are therefore propelling the growth of the CA Tumor Markers Testing Market.

For More Queries About "CA Tumor Markers Testing Market" @


In February 2022, BD (Becton, Dickinson and Company) declared the acquisition of Cytognos. The acquisition of Cytognos advances BD’s strategy to back chronic disease handling.

CA Tumor Markers Testing Market: Competitive Landscape

Key companies holding major shares in the CA Tumor Markers Testing Market are Abbott Laboratories, Becton, Dickinson and Company, Applied Genetic Technologies Corporation, bioMérieux SA, Cepheid, Correlogic Systems, Inc., Myriad Genetics, Panacea Pharmaceuticals, Qiagen and Radiant Pharmaceuticals.

To request for a quote, provide your details in the below link:

Media Contact:
Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.